Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Inclusion Criteria: * PRE-SCREENING: Documented informed consent of the participant and/or legally authorized representative * PRE-SCREENING: Age ≥ 18 years * PRE-SCREENING: Participant was diagnosed with Ph+ ALL according to World Health Organization criteria. The BCR::ABL1 translocation may be detected by fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next generation sequencing (NGS), or cytogenetics at least once any time prior to cellular therapy. Participants may have p190 or p220 isoform, and participants with T315I mutation are not excluded * PRE-SCREENING: Participant meets one of the following criteria: * Arm 1: Have a date for HSCT scheduled within the next 30 days or have received HSCT within the last 30 days. Note: all HSCT donors, conditioning regimens, and GVHD prophylaxis regimens will be acceptable. * Arm 2: Have a date for CAR T cell infusion scheduled within the next 30 days or have received CAR T cell infusion within the last 30 days * PRE-SCREENING: History of pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis * PRE-SCREENING: History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent * PATIENTS AFTER DAY +30 FOLLOWING CELLULAR THERAPY: Documented informed consent of the participant and/or legally authorized representative. * Assent, when appropriate, will be obtained per institutional guidelines * PATIENTS AFTER DAY +30 FOLLOW…